MX2009003815A - Formulaciones farmaceuticas. - Google Patents

Formulaciones farmaceuticas.

Info

Publication number
MX2009003815A
MX2009003815A MX2009003815A MX2009003815A MX2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
active agent
formulation
dissolution
salt
Prior art date
Application number
MX2009003815A
Other languages
English (en)
Spanish (es)
Inventor
Dennis Y Lee
Yi Gao
R Ju Tzuchi
Nicole Nguyen
Hauiliang Wu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2009003815A publication Critical patent/MX2009003815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009003815A 2006-10-12 2007-10-12 Formulaciones farmaceuticas. MX2009003815A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12
PCT/US2007/081267 WO2008046052A1 (en) 2006-10-12 2007-10-12 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MX2009003815A true MX2009003815A (es) 2009-09-07

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003815A MX2009003815A (es) 2006-10-12 2007-10-12 Formulaciones farmaceuticas.

Country Status (14)

Country Link
EP (1) EP2081563A1 (ko)
JP (1) JP2010506855A (ko)
KR (1) KR20090119959A (ko)
CN (1) CN101677981A (ko)
AU (1) AU2007307641A1 (ko)
CA (1) CA2672686A1 (ko)
CO (1) CO6160302A2 (ko)
EA (1) EA200900531A1 (ko)
EC (1) ECSP099251A (ko)
IL (1) IL198160A0 (ko)
MX (1) MX2009003815A (ko)
SG (1) SG175570A1 (ko)
WO (1) WO2008046052A1 (ko)
ZA (1) ZA200902488B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0912161A2 (pt) * 2008-05-30 2015-10-06 Ucb Pharma Sa composição farmacêutica na forma de um tablete
CN102304103A (zh) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸盐、制备方法、药物组合物及应用
CN102659570B (zh) * 2012-05-17 2014-05-28 安润医药科技（苏州）有限公司 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1832285A1 (en) * 2002-12-17 2007-09-12 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
CN101480384A (zh) * 2002-12-17 2009-07-15 阿伯特有限及两合公司 包含非诺贝酸、其生理可接受的盐或衍生物的制剂
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
SG161256A1 (en) * 2005-04-08 2010-05-27 Abbott Lab Oral pharmaceutical formulations comprising fenofibric acid and/or its salts

Also Published As

Publication number Publication date
ECSP099251A (es) 2009-06-30
EA200900531A1 (ru) 2009-12-30
AU2007307641A1 (en) 2008-04-17
KR20090119959A (ko) 2009-11-23
JP2010506855A (ja) 2010-03-04
IL198160A0 (en) 2009-12-24
CN101677981A (zh) 2010-03-24
WO2008046052A1 (en) 2008-04-17
CA2672686A1 (en) 2008-04-17
EP2081563A1 (en) 2009-07-29
CO6160302A2 (es) 2010-05-20
ZA200902488B (en) 2010-10-27
SG175570A1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
MX350380B (es) Formas de dosificacion solida de liberacion modificada en el orden de cero.
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
IN2012DN01216A (ko)
WO2008137758A3 (en) Amino acid lipids and uses thereof
WO2009060608A1 (ja) Ｓｄｆ－１を含有してなる徐放性組成物
WO2007036952A3 (en) Novel sustained release dosage form
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
NZ610701A (en) Once daily formulation of lacosamide
EP1713450A4 (en) FAST DISSOLVING FILM FOR THE DELIVERY OF ACTIVE AGENT
MX2009013019A (es) Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica.
WO2006116718A3 (en) Pharma-informatics system
MX2009003815A (es) Formulaciones farmaceuticas.
PT1834635E (pt) Sistemas estáveis de nanocápsula para a administração de moléculas activas
WO2007008220A8 (en) Gene or drug delivery system
WO2007095041A3 (en) Pharmaceutical formulations
WO2011101866A3 (en) Gastric retention formulation containing baclofen
WO2009047802A3 (en) Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
MX2013001985A (es) Formulaciones a base de nalbufina y sus usos
PT1795186E (pt) Preparado farmacêutico compreendendo flupirtina com libertação controlada da substância activa
WO2012092486A3 (en) Modified release benzimidazole formulations
WO2007065625A3 (en) Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations
NZ611026A (en) Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
FR2967576B1 (fr) Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament

Legal Events

Date Code Title Description
FA Abandonment or withdrawal